.svg)
As a postmenopausal woman, your health priorities may have shifted, and managing your well-being often involves balancing several factors. If you're using GLP-1 medications like semaglutide to manage weight or diabetes, you might be wondering about their impact on other aspects of your health like bone health. Their role in supporting metabolic health is increasingly recognised. These medications mimic the natural hormone GLP-1, which helps regulate blood sugar by promoting insulin secretion, slowing gastric emptying, and curbing appetite. This makes them an especially useful option for individuals struggling with obesity.
For postmenopausal women, though, there’s another layer to consider. Bone health becomes a particular concern during and after menopause due to the decline in oestrogen, which can accelerate bone loss and increase the risk of fractures. What’s fascinating is the emerging research suggesting that GLP-1 agonists may actually have a protective effect on bones.
Mechanisms like reducing inflammation, improving insulin sensitivity, and even influencing gut microbiota are being explored for their potential to benefit bone metabolism. This could provide a unique advantage for postmenopausal women who are trying to manage both weight and bone density at the same time. If you're navigating this concern, you're not alone. Understanding how GLP-1 medications might interact with your bones can help you make informed decisions about your treatment plan. Lets explore further the relationship between the GLP1 medications and bone health.
GLP-1 Agonists and Bone Density - Current Research
Research on the impact of GLP-1 agonists on bone mineral density is still developing but shows promising results. A study indicated that patients treated with GLP-1RAs exhibited an increase in bone mineral density (BMD) compared to those not receiving these medications. This suggests a potential protective effect on bones, which is crucial for postmenopausal women who are at higher risk for osteoporosis.
Potential mechanisms of action include:
- Changes in Gut Microbiota: Recent studies suggest that GLP-1RAs may positively influence gut microbiota composition, which has been linked to improved metabolic health and possibly enhanced bone density . A balanced gut microbiome can play a role in nutrient absorption and inflammation reduction, both critical for maintaining healthy bones.
- Hormonal Balance: GLP-1 agonists may also affect hormones involved in bone metabolism. They can influence levels of insulin and glucagon, both of which are known to play roles in bone remodelling processes.
Potential Benefits
The potential benefits of GLP-1 agonists on bone health extend beyond mere increases in BMD:
- Reduced Inflammation: Chronic inflammation is a known contributor to bone loss. GLP-1 agonists possess anti-inflammatory properties that may help mitigate this risk, potentially leading to better outcomes for bone health .
- Improved Insulin Sensitivity: Enhanced insulin sensitivity is another mechanism through which GLP-1 agonists may benefit bone health. Insulin plays a role in osteoblast function (cells responsible for bone formation), suggesting that improved insulin sensitivity could support better bone density .
Potential Risks
Despite the potential benefits, there are concerns regarding the use of GLP-1 agonists in individuals with pre-existing bone conditions:
- Fracture Risk: Some studies have raised questions about whether long-term use of GLP-1RAs might be associated with an increased risk of fractures. For instance, while there was no direct correlation between GLP-1 therapy and increased fracture rates observed in some studies, caution is warranted when prescribing these medications to individuals with existing osteoporosis or high fracture risk.
Compatibility with Osteoporosis Medications
When considering the use of GLP-1RAs in patients undergoing treatment for osteoporosis, it is essential to review potential interactions with commonly prescribed osteoporosis medications, such as bisphosphonates and denosumab.
- Bisphosphonates: These medications, including alendronate and risedronate, are commonly used to prevent bone loss and reduce fracture risk. Current research suggests that there are no significant interactions between GLP-1RAs and bisphosphonates. In fact, some studies indicate that GLP-1RAs may complement the effects of bisphosphonates by enhancing bone formation while reducing bone resorption, potentially leading to improved bone density outcomes .
- Denosumab: This medication works by inhibiting osteoclast formation and activity, thereby reducing bone resorption. Similar to bisphosphonates, there is limited evidence suggesting that GLP-1RAs do not negatively impact the efficacy of denosumab. However, monitoring is essential to ensure that the combined effects do not lead to unforeseen complications or adverse effects.
Combined Therapy
The potential benefits of combining GLP-1 agonists with osteoporosis treatments warrant further exploration.
- Potential Benefits: Combining GLP-1RAs with osteoporosis medications may enhance overall treatment efficacy. For instance, a study indicated that treatment with liraglutide not only improved glycemic control but also had positive effects on bone metabolism by increasing osteoblast proliferation and decreasing osteoclast activity . This dual action could lead to better management of both diabetes and osteoporosis.
- Need for Further Research: Despite the promising findings, more research is necessary to evaluate the efficacy and safety of such combinations. Current studies have shown mixed results regarding the impact of GLP-1RAs on bone health; some suggest positive effects on bone density, while others indicate no significant change or even potential risks in specific populations. Therefore, comprehensive clinical trials are needed to establish clear guidelines on the combined use of GLP-1RAs and osteoporosis treatments.
Monitoring Bone Health
Regular Bone Density Scans
For postmenopausal women, regular bone density assessments are vital for monitoring bone health and preventing osteoporosis-related fractures.
- Importance of Regular Assessments: The Royal Osteoporosis Society women aged 65 and older should undergo bone density testing at least once every two years or more frequently if they have risk factors for osteoporosis . Early detection of low bone density allows for timely intervention, which can significantly reduce the risk of fractures.
- Factors Influencing Frequency: Several factors may influence how often a woman should have her bone density scanned:
- Age: Older women are at higher risk for osteoporosis.
- Family History: A family history of fractures or osteoporosis can necessitate more frequent monitoring.
- Lifestyle Factors: Smoking, excessive alcohol consumption, and lack of physical activity can increase fracture risk.
- Medications: Certain medications (e.g., long-term corticosteroids) can affect bone density.
Lifestyle Factors
Maintaining a healthy lifestyle plays a crucial role in preserving bone health:
- Diet: A balanced diet rich in calcium and vitamin D is essential for bone health. Foods such as dairy products, leafy greens, and fortified foods can help meet these nutritional needs.
- Exercise: Regular weight-bearing exercises contribute significantly to maintaining or improving bone density. Activities like walking, jogging, and resistance training can stimulate bone formation and enhance strength.
- Vitamin D Supplementation: Adequate vitamin D levels are critical for calcium absorption and bone health. Supplementing vitamin D may be necessary for individuals who have limited sun exposure or dietary intake.
- Role of GLP-1 Agonists: GLP-1 agonists may contribute positively to a healthy lifestyle by promoting weight loss and improving metabolic health. Studies have shown that individuals using GLP-1RAs often engage in healthier eating habits and increased physical activity due to improved energy levels and reduced appetite.
Conclusion
The multifaceted role of GLP-1 receptor agonists in managing diabetes and weight loss, particularly focus on their potential impact on bone health. GLP-1 agonists have shown promise in improving bone mineral density and overall bone quality, which is especially important for postmenopausal women who face an increased risk of osteoporosis.
Research indicates that GLP-1RAs may promote bone formation and inhibit bone resorption through various mechanisms, such as reducing inflammation and improving insulin sensitivity. However, it is essential to approach the use of GLP-1 agonists with caution, particularly when considering their compatibility with osteoporosis treatments.
Consulting with a healthcare provider is crucial to assess individual risk factors and determine the appropriate course of action. Reach out to us at SheMed for personalised support and guidance, and don’t forget to share our blogs with friends and family who might benefit from this information
References
- NCBI Bookshelf Title: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Continuing Education Activity Source: National Center for Biotechnology Information (NCBI) Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/
- Zhang, Y., Chen, Y., Wang, Y., Liu, Z., & Zhang, H. Title: The Role of GLP-1 Receptor Agonists in the Treatment of Obesity Source: PMC9945324. National Center for Biotechnology Information (NCBI) Bookshelf. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9945324/
- Xu, Y., Wang, Y., Zhang, H., Yang, J., & Liu, Y. Title: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density Source: PMC8464416. National Center for Biotechnology Information (NCBI) Bookshelf. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8464416/
- Zhao, L., & Zhu, W. (2017). Effects of GLP-1 and GLP-1 receptor agonists on bone metabolism and bone fracture. Journal of Diabetes Research, 2017, Article 9282015. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5413504/
- Zhao, B., Liu, J., & Cai, L. (2023). The role of GLP-1 receptor agonists in cardiovascular health: Mechanisms and therapeutic potential. Frontiers in Cardiovascular Medicine, 10, 10230051. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10230051/
- Chakera, A. J., & Hurst, C. H. (2022). Advances in GLP-1 receptor agonists: Efficacy and safety in the treatment of obesity and type 2 diabetes. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9589410/
- Stern, J. H., & Smith, G. I. (2023). Insights into GLP-1 receptor agonists and metabolic health: Journal of Clinical Investigation, 133(9), e179942. Available at: https://www.jci.org/articles/view/179942
- Frías, J. P., & Davies, M. J. (2021). Tirzepatide: A glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Diabetes Therapy, 12(10), 2513–2530. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8525927/
- Perakakis, N., & Mantzoros, C. S. (2023). Novel insights on GLP-1 receptor agonists and GIP in obesity and diabetes: Nature Reviews Endocrinology, 19(3), 163–180. Available at: https://pubmed.ncbi.nlm.nih.gov/38367743/
- Taylor, J. J. (2019). Mechanisms of GLP-1 action and the impact on type 2 diabetes. In GLP-1 receptor agonists in type 2 diabetes (Table 1). StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532080/table/table1/
When new medical studies are released, they can feel full of numbers and complex terms. At SheMed, our role is to help you understand what they really mean for you, your health, and your future.
Recently, Novo Nordisk released the results of the STEER study, one of the most significant pieces of research yet on GLP-1 medicines like Wegovy. And the findings show something powerful: Wegovy is not only about weight loss, it’s also about heart health.
The Big Picture: What the STEER Study Looked At
The STEER study explored how GLP-1 medicines affect heart health in people living with Overweight or Obesity and established cardiovascular disease (but without diabetes).
Researchers compared Wegovy (Semaglutide 2.4mg) with Tirzepatide (Mounjaro). They focused on the risk of serious heart problems, what doctors call “major adverse cardiovascular events” (MACE). These include:
- Heart attack
- Stroke
- Death from heart disease
What They Found
The results were striking:
- For people who stayed on treatment without big gaps, Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% more than Mounjaro.
- When looking at all treated people, even those with breaks in care Wegovy still showed a 29% reduction in these serious events overall.
In short, Wegovy is not only helping people lose weight, it is also showing clear cardiovascular protection, especially when used consistently.
Why This Matters for You
We’ve always known GLP-1 medicines are powerful tools for weight loss, but the STEER study highlights something even bigger: they can also protect your heart. For anyone living with Obesity and cardiovascular disease, this is game-changing.
It also reinforces an important truth - long-term commitment matters most. The people who saw the greatest benefits were those who stayed consistent with their medication. That’s why at SheMed, we design every part of our programme to keep you supported, motivated, and engaged for the long run.
The SheMed Difference: Seeing the Bigger Picture
Medication is only one part of your health journey. At SheMed, we combine Wegovy with wraparound care:
- Regular blood tests to track key markers like cholesterol, blood sugar, and liver health.
- Weekly check-ins and app reminders to help you stay on track.
- Education and content designed specifically for women, covering sleep, hormones, activity, and nutrition.
- Proactive Side effect care and support to keep you comfortable and supported as your body adjusts.
This holistic approach matters because weight loss is just one marker of progress. By running blood tests before starting the programme, at 6 months, and 12 months, we can show you the deeper changes happening inside your body, improvements in cholesterol, blood sugar, and overall metabolic health.
It means you’ll see the true value of GLP-1s, not just in how you look or feel, but in the measurable ways your health is improving and your risks are reducing.
Why Wegovy Through SheMed Makes Sense
At SheMed, we’ve worked hard to make Wegovy accessible and affordable. With static, transparent pricing across doses, our members know exactly what they’re paying. That means no hidden surprises and no price hikes as you move up through titration.
When you combine that cost benefit with the evidence from STEER that Wegovy offers not just weight loss but cardiovascular protection the case for choosing Wegovy through SheMed becomes even stronger.
You’re not just investing in weight management; you’re investing in heart health, future health, and a programme designed to keep you safe and supported every step of the way.
The Future of Health With SheMed
The STEER study is a reminder that the story of GLP-1s is still unfolding and it’s about so much more than weight loss. These medicines are changing how we think about obesity, cardiovascular health, and long-term wellbeing.
At SheMed, we’ll continue to keep you informed as new research emerges, but more importantly, we’ll keep showing you the bigger picture through your own results. With every blood test, every milestone, and every step forward, you’ll see how far you’ve come not just in weight, but in health.
Because at SheMed, you’re not just losing weight. You’re gaining health, protecting your future, and building the strongest version of you.
Wegovy has quickly become a key treatment option in obesity management, particularly for adults living with excess weight and health conditions linked to obesity.
With recent price increases for Mounjaro®, another GLP-1 medication, many patients and healthcare providers are now turning to Wegovy as a strong alternative.
Clinical research shows that Wegovy can deliver significant weight loss results, often comparable to those seen with Mounjaro, making it one of the most effective options currently available.
Recent news and clinical trial data reveal that higher doses of Wegovy specifically at 7.2 mg weekly, have led to average weight loss of around 21% in adults with obesity, with approximately one-third of participants achieving a weight loss of 25% or more over 72 weeks. This is notably greater than the 15% average weight loss seen at the standard 2.4 mg dose.
Latest Clinical Data on Higher Doses
The 2025 STEP UP phase 3b trial evaluated semaglutide at both 7.2 mg and 2.4 mg weekly doses versus placebo in people with obesity who did not have diabetes. The results indicated a clear dose-response effect:
- Mean weight loss was 21% at 7.2 mg, compared to 17.5% at 2.4 mg, and much lower with placebo.
- Specifically, 51% of those on 7.2 mg lost at least 20% of their body weight, and 33% achieved a reduction of 25% or more.
- For 2.4 mg, 35% lost 20% or more, and 17% achieved 25% or greater weight loss.
Regulatory and Safety Considerations
- Novo Nordisk has announced plans to seek regulatory approval for the higher 7.2 mg dose in the EU and other regions in late 2025.
- Safety and tolerability of the 7.2 mg weekly dose were consistent with the known profile of semaglutide, with gastrointestinal side effects remaining most common, except for a low discontinuation rate for adverse effects (about 3%).
- These findings extend the potential of Wegovy for people requiring greater degrees of weight loss, emphasising the dose-dependent effect of semaglutide GLP-1 therapy.
Comparing New findings with Mounjaro
At higher doses (7.2 mg), Wegovy has demonstrated weight loss outcomes that closely mirror those achieved with Mounjaro. Clinical data show an average 21% reduction in body weight over 72 weeks with Wegovy, with around half of patients reaching at least 20% weight loss. By comparison, Mounjaro studies report average reductions of up to 22–23% at higher doses over a similar treatment duration. While Wegovy’s 7.2 mg dose remains under regulatory review and is not yet standard practice, these findings highlight that patients considering a switch may be able to achieve results that are highly comparable to those seen with Mounjaro, offering another strong option in pharmacological obesity management.
Head-to-head style snapshot (72-week outcomes)
In conclusion, if you are considering switching from Mounjaro to Wegovy, now is an excellent opportunity. Wegovy offers a highly effective alternative for weight management with similar clinical results, and - importantly - comes at a considerably lower price, especially as Mounjaro prices are set to rise sharply in the UK from September 2025. Choosing Wegovy can help maintain your weight loss goals while making your treatment more affordable.
If you have any questions or need personalised advice about making the switch, please do not hesitate to contact the Shemed support team at support@shemed.com.
References
- ClinicalTrials.gov. (2024, December 12). A research study to see how semaglutide helps people with excess weight, lose weight (STEP UP) (NCT05646706). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05646706
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Wadden, T. A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- American Diabetes Association (ADA). (2025, June). STEP UP trial: Semaglutide 7.2 mg in adults with obesity without type 2 diabetes [Conference presentation]. ADA 85th Scientific Sessions, Chicago, IL. Retrieved from https://diabetesjournals.org/ (poster abstract ePoster 446-P).
- Novo Nordisk. (2025, June 9). Semaglutide 7.2 mg shows ~21% weight loss at 72 weeks in STEP UP trial [Press release]. Retrieved from https://www.novonordisk.com/